# Annovis Bio (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter ended June 30, 2024. The company reported productive recent months, with encouraging data on lead compound buntanetap’s performance […] 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/annovis-bio-nyse-anvs-announces-encouraging-clinical-trial-results-ip-portfolio-enhancement/)
                    

[Newsramp.com TLDR](None) 

https://www.reddit.com/r/Business_NewsRamp/comments/1f2hfx8/annovis_bio_nyse_anvs_reports_encouraging_results/